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Reduction of Myeloperoxidase Activity by
Melatonin and Pycnogenol May Contribute to
their Blood Pressure Lowering Effect
To the Editor:
In a recent issue of Hypertension, Rezzani et al reported that
6 weeks of treatment with either melatonin or pycnogenol, a pine
bark extract rich in flavonoids, protected structure and function
of the microvasculature in spontaneously hypertensive rats and
resulted in a reduction in systolic blood pressure.1 These effects
were ascribed to the antioxidant properties of both compounds
that reduce oxidative stress and increase the availability of nitric
oxide by several mechanisms as depicted in the figure in the
accompanying editorial.2 We would like to propose reduction of
the activity of the oxidative enzyme myeloperoxidase (MPO) as
an additional mechanism.
MPO, an enzyme linked to both inflammation and oxidative
stress, catalyzes the production of hypochlorous acid and a range
of other highly reactive species, which, by killing pathogens,
play a protective role in the innate immune response. In the
vasculature, however, these MPO-derived reactive substances
may lead to structural damage and reduce the bioavailability of
the endogenous vasodilator nitric oxide. Accordingly, MPO is
associated with the initiation and propagation of cardiovascular
disease.3 We recently observed a positive association between
levels of MPO and both systolic and diastolic blood pressure in
a population-based cohort of elderly subjects.4 Because hydrogen
peroxide is an obligate cosubstrate of MPO, the activity of MPO
in the vasculature is enhanced by increased local production of
reactive oxygen species. In other words, MPO has the ability to
amplify oxidative stress, by using hydrogen peroxide to form
reactive oxidant species with a higher oxidative potential. In
accordance with this notion, the relationship between MPO and
blood pressure was strongest in individuals with features asso-
ciated with increased oxidative stress, such as obesity, low levels
of high-density lipoprotein cholesterol, the metabolic syndrome,
and type 2 diabetes.4
Interestingly, Galijasevic et al identified melatonin as a potent
inhibitor of MPO.5 They showed that, at physiological and
supplemental concentrations, melatonin interferes with the cata-
lytic activity of MPO by multiple pathways, including switching
the activity of MPO from peroxidation to catalase-like activity
and conversion of MPO to an inactive form.
Next to inhibition of MPO, melatonin may also reduce the
activity of MPO in the vasculature by 2 other mechanisms that
may also apply to pycnogenol. First, both compounds are
potent scavengers of reactive oxygen species and may thereby
limit the production of hydrogen peroxide, the cosubstrate of
MPO. Second, the antiinflammatory properties of melatonin and
pycnogenol may reduce infiltration of the vascular wall by
MPO-secreting leukocytes.
In summary, we propose that, in addition to the mechanisms
suggested by Rezzani et al, a reduction of vascular MPO activity
likely contributes to the vasoprotective and blood pressure–
lowering effects of melatonin and pycnogenol.
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